Site feasibility reviews are critical to identifying potential challenges before trial initiation. These assessments ensure that selected clinical trial sites possess the infrastructure, resources, and motivation to meet study requirements. However, sponsors and CROs often face difficulties when red flags are overlooked during this stage. This article outlines common warning signs during site feasibility reviews and offers guidance on how to address them to ensure successful site selection.

What is a Site Feasibility Review?

Site feasibility reviews evaluate a site’s suitability to conduct a specific clinical trial. These reviews gather data on infrastructure, staffing, patient population, and past performance. A comprehensive feasibility process helps sponsors minimize protocol deviations, recruitment failures, and regulatory issues.

The review may include feasibility questionnaires, telephone interviews, and pre-selection visits. When red flags are missed, costly delays and trial quality issues can arise.

Top Red Flags to Identify and Address:

1. Incomplete or Generic Feasibility Questionnaire Responses

• Missing data or vague answers in key sections like patient population, recruitment plans, or IRB timelines
• Responses that mirror template language without site-specific customization
• Contradictions between staff experience and protocol complexity

This often reflects a lack of engagement or familiarity with the protocol and should trigger a follow-up.

2. Limited Access to Target Patient Population

• Low patient numbers in the relevant indication over the past year
• Dependence on referrals without clear agreements or past success
• Limited access to databases for identifying eligible patients

This red flag suggests the site may struggle with enrollment timelines and retention goals.

3. High Staff Turnover or Resource Constraints

• Frequent changes in principal investigator (PI) or study coordinators
• Insufficient dedicated staff for clinical research tasks
• Part-time or overloaded study team members

Such sites may face issues with protocol adherence, data entry delays, and missed visits.

4. Weak Regulatory or Audit History

• Previous FDA or MHRA warning letters
• Repeated GCP violations or unresolved audit findings
• Poor record-keeping or protocol deviations

Always review the site’s compliance history and request any past audit reports.

5. Inadequate Infrastructure and Equipment

• Lack of temperature-controlled drug storage or uncalibrated equipment
• No backup systems for power, internet, or data access
• Shared research space with limited patient privacy

Such constraints affect drug accountability, data integrity, and patient comfort.

6. Overlapping Trials or Competing Commitments

• Multiple ongoing studies in the same therapeutic area
• Enrollment competition from similar protocols
• PI listed on too many active studies

Feasibility responses should account for site capacity and include realistic recruitment estimates.

7. Lack of Protocol Familiarity or PI Engagement

• PI is unavailable for feasibility calls or discussions
• Inability to answer basic protocol questions
• Reluctance to commit time for site qualification visits

Engaged investigators are vital for compliance and study success.

8. Delayed or Conditional Ethics Approval Process

• Sites that rely on external or infrequent IRB meetings
• Delays in past approval cycles for similar studies
• No clarity on local IRB submission process

Slow approval timelines can delay First Patient In (FPI) and project milestones.

How to Evaluate and Manage Red Flags:

1. Scoring and Documentation

Assign weighted scores to critical factors such as patient access, staffing, and PI experience. Document reasons for site disqualification or conditional approval.

2. Conduct Clarification Calls

If feasibility responses are ambiguous, schedule a feasibility interview with the PI and key staff. Clarify gaps and assess motivation firsthand.

3. Request Additional Documents

Ask for supplemental evidence such as past enrollment logs, site SOPs, and regulatory correspondence. This helps validate feasibility claims.

4. Use a Standardized Checklist

Standardized checklists aligned with Pharma SOP templates improve consistency across site assessments.

5. Consider Backup Sites

Always qualify a secondary list of sites to mitigate risks associated with high-risk or borderline locations.

Examples of Red Flag Scenarios:

Example 1: A site claims access to 100+ patients but cannot show any recruitment success for similar trials. This may indicate overestimation or marketing hype.

Example 2: A high-performing investigator is listed, but is also running five concurrent trials with limited support staff. The capacity to deliver quality data may be compromised.

Example 3: A rural hospital site lacks centrifuge equipment and contracts out lab work, causing delays in biosample shipments. This could pose problems for stability-sensitive samples requiring Stability Studies compliance.

Conclusion:

Identifying red flags early during the feasibility review phase is critical to clinical trial success. Whether it’s understaffing, infrastructure gaps, or regulatory weaknesses, each red flag provides insight into potential operational or compliance risks. Sponsors and CROs must combine structured tools, direct communication, and scoring systems to make data-driven site selection decisions. With a robust feasibility review process in place, study teams can minimize delays and ensure quality outcomes from the very start.